Samlyn Capital, LLC Nektar Therapeutics Transaction History
Samlyn Capital, LLC
- $5.62 Billion
- Q2 2024
A detailed history of Samlyn Capital, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Samlyn Capital, LLC holds 9,457,887 shares of NKTR stock, worth $12.4 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
9,457,887Holding current value
$12.4 Million% of portfolio
0.21%Shares
1 transactions
Others Institutions Holding NKTR
# of Institutions
140Shares Held
135MCall Options Held
32.8KPut Options Held
55.5K-
Deep Track Capital, LP Greenwich, CT17.9MShares$23.4 Million0.73% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$19.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$17 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA7.53MShares$9.86 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.95MShares$9.11 Million0.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $246M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...